Not finding it? Sign in to also search OpenAlex live.
-
Secondary-Type Mutations Do Not Impact the Favorable Outcome of NPM1-Mutated Acute Myeloid Leukemia Patients - Results from a Large Cohort of Intensively Treated Patients
Marius Bill, Jan‐Niklas Eckardt, Christian R. Rausch, Klaus Hans Metzeler, Karsten Spiekermann, Sebastian Stasik, +34 more
3citations -
Trial in Progress: A Randomized-Controlled Phase 2 Study Evaluating Venetoclax Plus Azacitidine Versus Intensive Chemotherapy in Adult Patients with Newly Diagnosed, NPM1-Mutated AML - the SAL/AMLCG Vincent Trial
Leo Ruhnke, Christoph Schliemann, Lars R. Fransecky, Björn Steffen, Martin Kaufmann, Andreas Burchert, +26 more
2citations -
Allogeneic Hematopoietic Cell Transplantation in Patients ≤ 60 Years with Intermediate-Risk Acute Myeloid Leukemia in First Remission - Results of the Randomized Etal-1 Trial-
Martin Bornhaeuser, Christoph Schliemann, Johannes Schetelig, Christoph Röllig, Michael Krämer, Bertram Glaß, +21 more
2citations -
Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia2021 Blood Advances article Biochemistry, Genetics and Molecular Biology Protein Tyrosine Phosphatases Open access cited by 1 patent
Sebastian Stasik, Jan‐Niklas Eckardt, Michael Krämer, Christoph Röllig, Alwin Krämer, Sebastian Scholl, +31 more
38citations -
Venetoclax-Azacitidine As Salvage Therapy and Bridge to Allogeneic Cell Transplantation in Relapsed/Refractory AML Compared to Historical Data of the SAL Registry Study
Julia Marie Unglaub, Richard F. Schlenk, Maher Hanoun, Hans Christian Reinhardt, Jan Moritz Middeke, Kerstin Schäfer‐Eckart, +30 more
4citations -
Randomized Phase II Study of All-Trans Retinoic Acid and Valproic Acid Added to Decitabine in Newly Diagnosed Elderly AML Patients (DECIDER trial): Predictive Impact of TP53 Status
Heiko Becker, Claudia Schmoor, Olga Grishina, Dietmar Pfeifer, Dennis Zimmer, Martina Margrit Crysandt, +27 more
3citations -
Remission and Survival after Single Versus Double Induction with 7+3 for Newly Diagnosed Acute Myeloid Leukemia: Results from the Planned Interim Analysis of Randomized Controlled SAL-Daunodouble Trial
Christoph Röllig, Björn Steffen, Nael Alakel, Regina Herbst, Richard Noppeney, Maher Hanoun, +32 more
5citations -
Genetic and Epigenetic Changes at Secondary Resistance after Continued Treatment in the Randomized Phase II Study of All-Trans Retinoic Acid (ATRA) and/or Valproic Acid (VPA) Added to Decitabine (DAC) in Newly Diagnosed Elderly AML Patients (DECIDER Trial)
Inga Hund, Maria Elena Hess, Julia Stomper, Gabriele Greve, Jan Mitschke, Christoph Niemöller, +13 more
0citations
25 results